ETV6 and signaling gene mutations are associated with secondary transformation of myelodysplastic syndromes to chronic myelomonocytic leukemia.
作者信息
Padron Eric, Yoder Sean, Kunigal Sateesh, Mesa Tania, Teer Jamie K, Al Ali Najla, Sekeres Mikkael A, Painter Jeffrey S, Zhang Ling, Lancet Jeffrey, Maciejewski Jaroslaw P, Epling-Burnette Pearlie K, Sotomayor Eduardo, Komrokji Rami S, List Alan F
机构信息
Department of Hematologic Malignancies, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FLImmunology Program, H. Lee Moffitt Cancer Center and Research Institute, and the University of South Florida, Tampa, FL.
Molecular Genomics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
出版信息
Blood. 2014 Jun 5;123(23):3675-7. doi: 10.1182/blood-2014-03-562637.
Abstract
摘要
相似文献
1
ETV6 and signaling gene mutations are associated with secondary transformation of myelodysplastic syndromes to chronic myelomonocytic leukemia.
Blood. 2014 Jun 5;123(23):3675-7. doi: 10.1182/blood-2014-03-562637.
2
Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia.
Leukemia. 2010 May;24(5):1062-5. doi: 10.1038/leu.2010.20. Epub 2010 Feb 25.
3
Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.
Clin Cancer Res. 2015 Aug 1;21(15):3541-51. doi: 10.1158/1078-0432.CCR-14-2203. Epub 2015 Apr 3.
4
ETV6 deletion is a common additional abnormality in patients with myelodysplastic syndromes or acute myeloid leukemia and monosomy 7.
Haematologica. 2012 Dec;97(12):1933-6. doi: 10.3324/haematol.2012.069716. Epub 2012 Aug 8.
5
Molecular similarity between myelodysplastic form of chronic myelomonocytic leukemia and refractory anemia with ring sideroblasts.
Haematologica. 2013 Apr;98(4):576-83. doi: 10.3324/haematol.2012.071506. Epub 2012 Oct 12.
6
Mutated and number of somatic mutations as possible indicators of progression to chronic myelomonocytic leukemia of myelodysplastic syndromes with single or multilineage dysplasia.
Haematologica. 2017 Sep;102(9):e332-e335. doi: 10.3324/haematol.2017.166124. Epub 2017 May 18.
7
PHF6 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia and acute myeloid leukemia.
Leuk Res. 2023 Apr;127:107044. doi: 10.1016/j.leukres.2023.107044. Epub 2023 Feb 15.
8
Heterogeneous patterns of CEBPalpha mutation status in the progression of myelodysplastic syndrome and chronic myelomonocytic leukemia to acute myelogenous leukemia.
Clin Cancer Res. 2005 Mar 1;11(5):1821-6. doi: 10.1158/1078-0432.CCR-04-1932.
9
ETV6 rearrangements are recurrent in myeloid malignancies and are frequently associated with other genetic events.
Genes Chromosomes Cancer. 2012 Apr;51(4):328-37. doi: 10.1002/gcc.21918. Epub 2011 Dec 8.
10
[Analysis and clinical significance of ETV6 rearrangement in myelodysplastic syndromes patients].
Zhonghua Xue Ye Xue Za Zhi. 2007 Dec;28(12):804-7.
引用本文的文献
1
Impact of ETV6 mutations on clinical outcomes in acute myeloid leukemia: a real-world retrospective cohort study.
Ann Hematol. 2025 Jun 21. doi: 10.1007/s00277-025-06451-6.
2
A Phenogenetic Axis that Modulates Clinical Manifestation and Predicts Treatment Outcome in Primary Myeloid Neoplasms.
Cancer Res Commun. 2022 Apr 26;2(4):258-276. doi: 10.1158/2767-9764.CRC-21-0194. eCollection 2022 Apr.
3
Genomic Landscape and Risk Stratification in Chronic Myelomonocytic Leukemia.
Curr Hematol Malig Rep. 2021 Jun;16(3):247-255. doi: 10.1007/s11899-021-00613-9. Epub 2021 Mar 3.
4
Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients.
Leukemia. 2020 May;34(5):1407-1421. doi: 10.1038/s41375-019-0690-7. Epub 2019 Dec 13.
5
Leveraging Single-Cell RNA Sequencing Experiments to Model Intratumor Heterogeneity.
JCO Clin Cancer Inform. 2019 Apr;3:1-10. doi: 10.1200/CCI.18.00074.
6
Myelodysplastic syndromes: advantages of a combined cytogenetic and molecular diagnostic workup.
Oncotarget. 2017 Mar 25;8(45):79188-79200. doi: 10.18632/oncotarget.16578. eCollection 2017 Oct 3.
7
Mutated and number of somatic mutations as possible indicators of progression to chronic myelomonocytic leukemia of myelodysplastic syndromes with single or multilineage dysplasia.
Haematologica. 2017 Sep;102(9):e332-e335. doi: 10.3324/haematol.2017.166124. Epub 2017 May 18.
8
CMML: Clinical and molecular aspects.
Int J Hematol. 2017 Jun;105(6):711-719. doi: 10.1007/s12185-017-2243-z. Epub 2017 Apr 28.
9
A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML).
Clin Cancer Res. 2016 Aug 1;22(15):3746-54. doi: 10.1158/1078-0432.CCR-15-2781. Epub 2016 Feb 8.
10
An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies.
Blood Cancer J. 2015 Jul 31;5(7):e333. doi: 10.1038/bcj.2015.53.
本文引用的文献
1
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes.
Leukemia. 2014 Feb;28(2):241-7. doi: 10.1038/leu.2013.336. Epub 2013 Nov 13.
2
Clinical and biological implications of driver mutations in myelodysplastic syndromes.
Blood. 2013 Nov 21;122(22):3616-27; quiz 3699. doi: 10.1182/blood-2013-08-518886. Epub 2013 Sep 12.
3
Clonal architecture of chronic myelomonocytic leukemias.
Blood. 2013 Mar 21;121(12):2186-98. doi: 10.1182/blood-2012-06-440347. Epub 2013 Jan 14.
4
Frequent pathway mutations of splicing machinery in myelodysplasia.
Nature. 2011 Sep 11;478(7367):64-9. doi: 10.1038/nature10496.
5
Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms.
Nature. 2009 Aug 13;460(7257):904-8. doi: 10.1038/nature08240. Epub 2009 Jul 20.
6
AML1 mutations induced MDS and MDS/AML in a mouse BMT model.
Blood. 2008 Apr 15;111(8):4297-308. doi: 10.1182/blood-2007-01-068346. Epub 2008 Jan 11.
7
Chronic myelomonocytic leukemia evolving from preexisting myelodysplasia shares many features with de novo disease.
Am J Clin Pathol. 2006 Nov;126(5):789-97. doi: 10.1309/FU04-P779-U310-R3EE.
8
Oncogenic NRAS rapidly and efficiently induces CMML- and AML-like diseases in mice.
Blood. 2006 Oct 1;108(7):2349-57. doi: 10.1182/blood-2004-08-009498. Epub 2006 Jun 8.
Zotero 插件